Oralin Buccal Insulin May Face Easier Regulatory Path Than Inhaled Insulins, Generex Consultant Predicts
This article was originally published in The Pink Sheet Daily
Executive Summary
Oralin exposes only the oral cavity to insulin, Generex consultant Fleming says. Generex will pursue international approvals first with a more limited data package than FDA requires. Phase IIb trials have started in type 2 diabetes.